Abstract
Purpose The standard 60-mg dose of fimasartan, a newly developed selective angiotensin II receptor blocker, is effective and safe for use in patients with mild to moderate hypertension. This study aimed to compare the efficacy and safety of low-dose (30 mg) fimasartan and placebo or valsartan (80 mg) for 8 weeks in patients with mild to moderate hypertension.
Methods In this randomized trial, 293 patients (219 men; mean age, 54.24 [9.77] years) with mild to moderate hypertension were enrolled. After randomization to receive 30-mg fimasartan (n = 115), placebo (n = 117), or 80-mg valsartan (n = 61), the treatment dose was kept constant without dose escalation for 8 weeks. The primary end point was improvement in sitting diastolic blood pressure (SiDBP) from baseline to 8 weeks that was compared between treatments with low-dose fimasartan and placebo. The secondary end point was the overall efficacy and safety of low-dose fimasartan compared with that of placebo or valsartan.
Findings At week 8, SiDBP changed by -9.93 (8.86) mm Hg in the fimasartan group and by -2.08 (9.47) mm Hg in the placebo group, which indicated significant antihypertensive efficacy (P < 0.0001). Efficacy was shown at week 4 as measured by SiDBP (-9.96 [7.73] vs -2.27 [7.85] mm Hg; P < 0.0001) or sitting systolic blood pressure (SiSBP) (-16.18 [14.44] vs -1.95 [13.48] mmHg; P < 0.0001) and at week 8 as determined by SiSBP (-15.35 [16.63] vs -2.30 [14.91] mm Hg; P < 0.0001). The fimasartan group exhibited more potent antihypertensive efficacy than the valsartan group both at week 4 (SiDBP, -9.96 [7.73] vs -6.53 [9.58] mm Hg [P = 0.0123]; SiSBP, -16.18 [14.4] vs -7.65 [12.89] mm Hg [P = 0.0002]) and at week 8 (SiDBP, -9.93 [8.86] vs -5.47 [8.96] mm Hg [P = 0.0021]; SiSBP, -15.35 [16.63] vs -7.49 [13.68] mm Hg [P = 0.0021]). Most treatment-emergent adverse events (TEAEs) were mild (89 of 95), and there were no serious TEAEs. The incidence of TEAEs was 19.1% in the fimasartan group, 22.6% in the placebo group, and 13.6% in the valsartan group, with no significant differences.
Implications Low-dose fimasartan (30 mg) was well tolerated during the study period with no significant TEAEs. Low-dose fimasartan had an effective blood pressure-lowering effect that was greater than that of 80-mg valsartan in patients with mild to moderate hypertension. ClinicalTrials.gov identifier: NCT01672476.
| Original language | English |
|---|---|
| Pages (from-to) | 1412-1421 |
| Number of pages | 10 |
| Journal | Clinical Therapeutics |
| Volume | 36 |
| Issue number | 10 |
| DOIs | |
| State | Published - 10 Nov 2014 |
Bibliographical note
Funding Information:This research was financially supported by Boryung Pharmaceutical Co Ltd. The sponsor supported the expenses for medicine, laboratory tests, and the clinical research coordinator. The study was initiated by Boryung Pharmaceutical and was designed, conducted, interpreted, and written by the authors under the supervision of Dr. S.-M. Kang. An external monitoring group was involved in the collection and analysis of data. Drs. J.-C. Youn and S.-M. Kang participated in data analysis and interpretation. Drs. J.-C. Youn, S.-H. Ihm, J.-H Bae, S.-M. Park, D.W. Jeon, B.-C. Jung, T.H. Park, N.H. Lee, J.-M. Song, Y.W. Yoon, E.S. Shin, K.C. Sung, I.H. Jung, W.B. Pyun, S.-J. Joo, W.J. Park, J.H. Shin, and S.-M. Kang participated in study design and acquisition of data. All the authors participated in drafting the article or revising it and approved the final version.
Publisher Copyright:
© 2014 Elsevier HS Journals, Inc. All rights reserved.
Keywords
- fimasartan
- hypertension
- placebo
- valsartan